GlobeNewswire

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement
02/11/2026
BOSTON and SAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
02/11/2026
WELLESLEY HILLS, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that [...]
Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation
02/11/2026
Former McKinsey associate partner and Aliaxis strategy leader to lead AI initiatives and pursue partnerships to advance pipeline programs BERKELEY HEIGHTS, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals [...]
Hinge Bio to Present Latest Results of HB2198, a Novel B-Cell Depleting Agent for Treating Autoimmune Disease, at ACR Convergence 2026
02/11/2026
Early clinical data and additional preclinical data of HB2198 will be presented at the American College of Rheumatology (ACR) Convergence 2026 REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a [...]
Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
02/11/2026
Trial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as compared to placebo [...]
Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome
02/11/2026
Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat Gan, Israel, Nov. [...]
Beeline Medicines Initiates First Trial in Lupus Pivotal Development Program with Global Phase 2/3 DISCOVERY Trial of Afimetoran in Cutaneous Lupus Erythematosus (CLE)
02/11/2026
– Afimetoran, an investigational oral, once-daily, equipotent TLR7/8 inhibitor, targets a central driver of lupus biology with the potential to address both cutaneous and systemic disease – – Global, randomized, double- [...]
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
02/11/2026
BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans [...]
Harrow Launches HarrowRx Platform
02/11/2026
HarrowRx to Simplify Access to Harrow Products and Integrate Into the Eyecare Practice Workflow, Providing a Single Prescribing Destination Within Existing Electronic Medical Record (EMR) Systems NASHVILLE, Tenn., Nov. [...]
Tilray Brands Announces Strategy to Strengthen Canadian Cannabis Operations and Drive Profitable Growth
02/11/2026
Consolidation of Foss Cultivation and Pre-roll Production into Optimized Masson and Cayuga Facilities Expected to Generate Approximately US$10 Million in Annualized Cost Savings Higher Cultivation Yields and Expected [...]
Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
02/11/2026
Presentations at AHA to highlight Lexeo's cardiovascular gene therapy pipeline, including preclinical programs in desmoplakin and TNNI3 cardiomyopathies New LX2006 data to be presented at ICAR demonstrating cardiac and [...]
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
02/11/2026
ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX ® Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1 [...]
ICPO ACADEMY FOR THERANOSTICS Launches Advanced Program in Radiomolecular Precision Oncology
02/11/2026
Online curriculum expands with advanced clinical cases in prostate cancer and neuroendocrine tumors including multidisciplinary tumor board illustrations Wiesbaden, November 2, 2026 – Radiomolecular Precision Oncology, [...]
OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care
02/11/2026
Collaboration will bring diagnostics expertise to a global, multi-stakeholder effort focused on policy, advocacy, and practical implementation BETHLEHEM, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc [...]
OraSure Technologies rejoint la Coalition mondiale contre la drépanocytose afin de favoriser l’accès à un diagnostic plus précoce et aux soins
02/11/2026
Cette collaboration apportera une expertise en matière de diagnostic à une initiative mondiale multipartite axée sur les politiques publiques, le plaidoyer et la mise en œuvre concrète des mesures. BETHLEHEM, [...]
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
02/11/2026
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron [...]
Nouscom Strengthens Leadership and Operational Capabilities, Appointing Loredana Siani, Ph.D., as Chief Technology Officer
02/11/2026
Nouscom Strengthens Leadership and Operational Capabilities, Appointing Loredana Siani, Ph.D., as Chief Technology Officer Promotion follows recent €120 million Series D financing as Nouscom advances NOUS-209 into [...]
CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2026
02/11/2026
DIJON, France CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique internationale spécialisée dans le développement d'auto-injecteurs sans aiguille pour les situations d'urgence, annonce avoir mis à [...]
CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2026
02/11/2026
DIJON, France CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique internationale spécialisée dans le développement d'auto-injecteurs sans aiguille pour les situations d'urgence, annonce avoir mis à [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum